Pallas Health Review

What Pallas Health charges

• Sermorelin: $597 — A TWELVE-WEEK CHARGE, not a month — "$89 for your first month, then $597 every 12 weeks ($199/mo average). Cancel anytime." ⛔ The $199 is the seller's own arithmetic on the $597 charge and it labels it "average"; a reader who records $199/mo drops the word the seller put there and hides a $597 billing event
• NAD+: $79 — A FIRST-MONTH FLOOR AND NOTHING ELSE — "Available as a clinician-prescribed injection or nasal spray, from $79 for your first month." ⛔ No ongoing rate is published for this compound anywhere on the page, so what a second month costs is not stated

It names the peptides it will not sell, and says why

Its guide names four of the most heavily marketed peptides online and states that they are not approved for any use and are not on the regulator's list of substances allowed in pharmacy compounding — which, it says, means no licensed pharmacy may lawfully prepare them.

It then explains what the research-use-only label is for: a legal framing that shifts risk to the buyer rather than a mark of legitimacy. That passage trips every grey-market pattern a classifier can carry, while saying the opposite of what such a pattern is looking for.

This is the fourth seller in this batch on which that inversion happens, and the sharpest. Categorising a seller from a keyword match would file the most careful writer in the batch alongside the vendors it is warning readers about.

It also corrects the error this whole vertical makes, in its own product copy: the coenzyme it sells is a coenzyme, not a peptide.

A quarterly charge that advertises itself as a monthly average

The growth-hormone peptide is sold as a discounted first month followed by a charge every twelve weeks. The seller prints the twelve-week charge and, in brackets, its own division of that charge into a monthly figure, labelled as an average.

The label is the important word and it is the one an extractor drops. A reader who records the monthly figure and discards "average" has recorded a billing event that does not happen.

This site records the twelve-week charge, because that is the amount that actually leaves an account, and puts the arithmetic in the qualifier.

The coenzyme line publishes a first-month floor and no ongoing rate at all, so what a second month costs is not stated anywhere on the page.

A two-compound catalogue, on purpose

Two compounds this site tracks are sold here, which is among the narrowest catalogues on the roster. The narrowness is the seller's argument rather than a gap.

It publishes per-state pages, which most of this roster lacks, but no coverage list — the terms say only that a clinician licensed in the reader's state reviews the intake.

The operating company is named in the terms and repeated in the footer, and it bears no relation to the brand. No pharmacy is named; partners are described by facility class.

How we verified this

• Fetched the peptides guide and the terms with a full browser user-agent, comparing the effective URL to the requested one on both.
• Fired a nonsense-path control at the host in the same run; it returned an honest not-found status.
• Joined the text nodes before matching and read all four dollar figures on the guide with the sentences around them.
• Read both places a research-use pattern fires in full, and confirmed the passage is an indictment of that market rather than a disclaimer.
• Kept the seller's own word "average" attached to its derived monthly figure rather than recording the figure alone.
• Read the operating company out of the service-description sentence in the terms and out of the footer.
• Screened the brand and the operating company against the regulator's live warning-letter index, with a known-positive and a nonsense control in the same run.